As flu season approaches, residents of Washington state may have a powerful new tool in their medical arsenal. A new mRNA flu vaccine called mFLUSIVA is rolling out specifically for adults aged 50 and older, utilizing the same groundbreaking technology found in COVID-19 vaccines. According to experts at UW Medicine, this updated approach is nearly 30 percent more effective than traditional shots for older adults who face a higher risk of hospitalization or death from the virus.
The need for such an advancement stems from a biological process known as immunosenescence, where the immune system naturally weakens with age and becomes less responsive to standard vaccinations. Dr. Deborah Fuller of UW Medicine explains that the mRNA version provides more durable protection by producing antibodies that can recognize a wider variety of influenza strains. This development comes at a critical time, as recent data shows that over 91 percent of flu-related deaths in Washington occurred in individuals over 50 during previous seasons.
Local residents say they are eager to avoid another grueling bout with the illness. Seattle resident Bob Aristarco noted that after experiencing the flu several times and dealing with days of sickness, he and his wife make it a priority to get vaccinated early every year. Others, like Chuck Gould, believe some of the public apprehension surrounding mRNA technology is unnecessary hysteria and view the new vaccine as a welcome example of how science continues to evolve and improve patient care.
While the benefits are significant, health providers note that patients should be aware of potential trade-offs. Clinical trials indicated that mFLUSIVA tends to cause stronger side effects than traditional shots, including increased fatigue as well as muscle and joint aches. Dr. Fuller suggests that anyone over 50 consult their physician or pharmacist before scheduling the appointment, particularly those who experienced severe reactions to previous mRNA injections.
Availability varies across the region, though major chains like CVS and Walgreens are beginning to stock the dose. While those 65 and older will likely find coverage through Medicare, it remains unclear which private insurers will cover the cost for adults between 50 and 64. Despite these logistical questions, medical professionals emphasize that any vaccine is far superior to remaining unprotected against a potentially deadly seasonal virus.
